Adni vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Singapore YC healthcare worker super app with 150K+ verified nurses for peer advice, jobs, and credential management at $1.8M ARR Jul 2025; $1.38M Flare Capital seed with Penn Medicine/MedPro partnerships competing with Doximity for allied health professionals.
About
Adni is a Singapore-headquartered AI-powered super app for healthcare workers — backed by Y Combinator with $1.38 million raised including a $1.25 million seed round in May 2022 from YC, Flare Capital Partners, and Fresco Capital — providing 150,000+ verified nurses and allied healthcare professionals with a unified platform for anonymous peer advice sharing, job discovery, credential management (universal professional profile storing licenses, certifications, and continuing education records), equipment procurement, and community resources, generating $1.8 million in annual revenue as of July 2025 with approximately 32 employees across Asia and North America. Adni partners with leading healthcare organizations including Penn Medicine, MedPro, and PRN Healthcare to provide nurses and allied health workers with the professional tools that their clinical training institutions and hospital employers don't provide.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.